Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angiotech buys Quill to integrate suture business

This article was originally published in The Gray Sheet

Executive Summary

Angiotech acquires Quill Medical for $40 mil. May 25. Vertical integration of minimally invasive wound closure device maker Quill follows closely on the heals of Angiotech's purchase of Quill distributor American Medical Instruments. AMI was acquired by Angiotech in March for $785 mil. as part of a strategy to expand direct device sales and become less reliant on royalty-based partnerships. AMI's Surgical Specialties unit markets privately held Quill's 510(k)-cleared Contour Thread, a self-anchoring polypropylene suture technology for minimally invasive "face lift" procedures, under a 2004 agreement. Angiotech plans to develop the Contour technology for use in additional aesthetic and general surgical applications. Angiotech notes it does not expect Quill to "materially impact" corporate sales in 2006 or 2007. With the AMI purchase, Angiotech forecasts total 2006 revenue of $325 mil. to $335 mil. - including nine months of AMI sales - and total 2007 revenue of $400 mil. to $425 mil...

You may also be interested in...



Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel